Additional information
| Use in sports | None |
|---|---|
| Formula | C18H19N3O |
| Side effects | Headache, constipation, dizziness |
| Effects | Prevents nausea and vomiting |
| Dosage (sports) | Not applicable |
| Dosage (medical) | Typically 8 mg administered 30 minutes before the start of chemotherapy, followed by a second dose 8 hours after the first, then 8 mg every 12 hours for 1 to 2 days after chemotherapy |
| Half-life | Approximately 4 hours |
| Main action | Antiemetic |
| Substance class | Serotonin 5-HT3 receptor antagonist |
| Chemical name | (RS)-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-2,3,4,9-tetrahydro-1H-carbazol-4-one |
| Water Retention | None |
| Storage conditions | Store at room temperature away from moisture and heat |
| Trade name | Zofran |
| Blood pressure | Generally has no effect on blood pressure |
| Also known as | Zofran |
| Strength | 4 mg |
| Lab Test | Not specifically required for monitoring ondansetron |
| Hepatotoxicity | Low |
| Manufacturer | Cipla |
Reviews
There are no reviews yet.